euro adhoc: curasan AG
Strategic management decisions
curasan AG enters into
Growth Market of Dental Implants
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
10.11.2005
Kleinostheim, November 10, 2005 - curasan AG (ISIN DE 000 549 453 8) listed in the Prime Standard, is going to expand its product line by a dental implant system.
The REVOIS all-in-one System will be presented to international experts on occasion of the 23. World Congress of the "International Congress of Oral Implantologists" (ICOI) in Strasbourg, France, starting today. REVOIS means "Revolutionary Implant System".
As a logical completion of the existing range, the market position achieved by the bone regeneration products will be utilised and extended for REVOIS.
The product launch is under preparation and will take place within the next few weeks.
end of ad hoc
About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. curasan AG's main goal is to occupy a leading position as a global specialist in Regenerative Medicine. For further information, please visit curasans corporate website at: www.curasan.de
end of announcement euro adhoc 10.11.2005 09:17:56
Further inquiry note:
Dr. Erwin Amashaufer
Tel.: +49(0)6027-4686-465
E-Mail: ir@curasan.de
Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
Berliner Wertpapierbörse / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade
Bremer Wertpapierbörse (BWB) / free trade